Y Intercept Hong Kong Ltd Cuts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Y Intercept Hong Kong Ltd lessened its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 52.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,525 shares of the biopharmaceutical company’s stock after selling 7,126 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Intra-Cellular Therapies were worth $545,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. True Wealth Design LLC purchased a new position in shares of Intra-Cellular Therapies in the 3rd quarter worth approximately $32,000. GAMMA Investing LLC boosted its holdings in shares of Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the period. Capital Performance Advisors LLP purchased a new position in shares of Intra-Cellular Therapies in the 3rd quarter worth approximately $74,000. Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies in the 4th quarter worth approximately $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Intra-Cellular Therapies in the 3rd quarter worth approximately $97,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their target price for the stock from $119.00 to $132.00 in a report on Friday, January 31st. JPMorgan Chase & Co. boosted their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $140.00 to $132.00 in a report on Monday, February 24th. Finally, StockNews.com initiated coverage on Intra-Cellular Therapies in a report on Monday, February 24th. They set a “hold” rating for the company. Ten research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Stock Down 0.0 %

Shares of NASDAQ ITCI opened at $128.20 on Friday. The business has a fifty day simple moving average of $114.58 and a two-hundred day simple moving average of $91.50. The firm has a market cap of $13.63 billion, a PE ratio of -147.35 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a twelve month low of $63.30 and a twelve month high of $129.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.